Lovastatin ( DrugBank: Lovastatin )


11 diseases
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病1
34神経線維腫症4
46悪性関節リウマチ1
79家族性高コレステロール血症(ホモ接合体)1
156レット症候群1
160先天性魚鱗癬1
195ヌーナン症候群1
206脆弱X症候群3
263脳腱黄色腫症1
280巨大動静脈奇形(頚部顔面又は四肢病変)1
310先天異常症候群1

6. パーキンソン病


臨床試験数 : 2,307 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03242499
(ClinicalTrials.gov)
May 15, 20171/8/2017Lovastatin as a Neuroprotective Treatment for Early Stage Parkinson's DiseaseLovastatin as a Neuroprotective Treatment for Early Stage Parkinson's Disease: a Single-center, Double-blind, Placebo-controlled Randomized TrialParkinson DiseaseDrug: Lovastatin;Drug: PlaceboNational Taiwan University HospitalNULLRecruiting30 Years90 YearsAll80Phase 2Taiwan

34. 神経線維腫症


臨床試験数 : 133 薬物数 : 186 - (DrugBank : 67) / 標的遺伝子数 : 79 - 標的パスウェイ数 : 190
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03826940
(ClinicalTrials.gov)
February 19, 201923/1/2019From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1Linking Inhibition From Molecular to Systems and Cognitive Levels: a Preclinical and Clinical Approach in Autism Spectrum Disorders and Neurofibromatosis.Autism Spectrum Disorder;Neurofibromatosis 1Drug: Lovastatin 60 MG;Drug: PlacebosUniversity of CoimbraNULLCompleted16 Years65 YearsAll16N/APortugal
2EUCTR2016-005022-10-DE
(EUCTR)
13/02/201809/11/2017Improvement of synaptic plasticity and cognitive function in RAS pathway disordersImprovement of synaptic plasticity and cognitive function in RAS pathway disorders Noonan Syndrom and Neurofibromatosis Type 1
MedDRA version: 20.0;Level: PT;Classification code 10029748;Term: Noonan syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 20.0;Classification code 10029268;Term: Neurofibromatosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Not possible to specify
Product Name: Lovastatin
INN or Proposed INN: Lovastatin
Other descriptive name: LOVASTATIN
Product Name: Lamotrigin beta
INN or Proposed INN: Lamotrigin
Technische Universität München, Fakultät für MedizinNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
30Phase 2Germany
3NCT00352599
(ClinicalTrials.gov)
September 200913/7/2006Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)Neurofibromatosis 1Drug: Lovastatin;Drug: placebo pillUniversity of California, Los AngelesNULLCompleted10 Years50 YearsBoth44Phase 1United States
4NCT00853580
(ClinicalTrials.gov)
July 200923/2/2009A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1Neurofibromatosis Type 1Drug: Lovastatin ™;Device: placeboUniversity of Alabama at BirminghamBoston Children's Hospital;Children's Hospital of Philadelphia;Children's National Research Institute;Children's Hospital Medical Center, Cincinnati;National Cancer Institute (NCI);University of Chicago;University of Utah;Washington University School of Medicine;Sydney Children's Hospitals Network;University of Texas Southwestern Medical CenterCompleted8 Years15 YearsAll146Phase 2United States;Australia

46. 悪性関節リウマチ


臨床試験数 : 4,356 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00302952
(ClinicalTrials.gov)
November 6, 200713/3/2006Lovastatin for the Treatment of Mildly Active Rheumatoid ArthritisA Double Blind, Placebo Controlled, Phase II, Randomized Study of Lovastatin Therapy in the Treatment of Mildly Active Rheumatoid ArthritisRheumatoid ArthritisDrug: Lovastatin;Drug: PlaceboNational Institute of Allergy and Infectious Diseases (NIAID)Autoimmunity Centers of ExcellenceTerminated18 Years70 YearsAll64Phase 2United States

79. 家族性高コレステロール血症(ホモ接合体)


臨床試験数 : 145 薬物数 : 114 - (DrugBank : 26) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 17
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03510715
(ClinicalTrials.gov)
August 31, 201818/4/2018An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial HypercholesterolemiaAn Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial HypercholesterolemiaHypercholesterolemiaDrug: Alirocumab SAR236553 (REGN727);Drug: Rosuvastatin;Drug: Ezetimibe;Drug: Cholestyramine;Drug: Nicotinic acid;Drug: Fenofibrate;Drug: Omega-3 fatty acids;Drug: Atorvastatin;Drug: Simvastatin;Drug: Fluvastatin;Drug: Pravastatin;Drug: LovastatinSanofiRegeneron PharmaceuticalsCompleted8 Years17 YearsAll18Phase 3Brazil;Canada;Denmark;Mexico;Netherlands;Russian Federation;Slovenia;Spain;Taiwan;Turkey;Austria;France;Italy;Norway;United States

156. レット症候群


臨床試験数 : 44 薬物数 : 61 - (DrugBank : 23) / 標的遺伝子数 : 57 - 標的パスウェイ数 : 83
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02563860
(ClinicalTrials.gov)
July 201520/7/2015Pharmacological Treatment of Rett Syndrome With StatinsPharmacological Treatment of Rett Syndrome With 3-Hydroxy-3 Methylglutaryl-coenzyme A Reductase Inhibitor-Lovastatin (Mevacor)Rett SyndromeDrug: LovastatinMontefiore Medical CenterRett Syndrome Research TrustCompleted3 YearsN/AFemale20Phase 2United States

160. 先天性魚鱗癬


臨床試験数 : 42 薬物数 : 71 - (DrugBank : 21) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 112
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01110642
(ClinicalTrials.gov)
July 201122/4/2010Novel Treatment for Syndromic IchthyosesOpen-label, Pilot Study to Assess Cholesterol-Lovastatin Solution in the Treatment of Syndromic IchthyosesSyndromic Ichthyoses;CHILD Syndrome;Smith Lemli Opitz Syndrome;Conradi SyndromeDrug: LovastatinNorthwestern UniversityNULLWithdrawn1 YearN/ABoth0Phase 2United States

195. ヌーナン症候群


臨床試験数 : 25 薬物数 : 23 - (DrugBank : 5) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 9
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-005022-10-DE
(EUCTR)
13/02/201809/11/2017Improvement of synaptic plasticity and cognitive function in RAS pathway disordersImprovement of synaptic plasticity and cognitive function in RAS pathway disorders Noonan Syndrom and Neurofibromatosis Type 1
MedDRA version: 20.0;Level: PT;Classification code 10029748;Term: Noonan syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 20.0;Classification code 10029268;Term: Neurofibromatosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Not possible to specify
Product Name: Lovastatin
INN or Proposed INN: Lovastatin
Other descriptive name: LOVASTATIN
Product Name: Lamotrigin beta
INN or Proposed INN: Lamotrigin
Technische Universität München, Fakultät für MedizinNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
30Phase 2Germany

206. 脆弱X症候群


臨床試験数 : 108 薬物数 : 91 - (DrugBank : 36) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 77
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02680379
(ClinicalTrials.gov)
March 201625/1/2016Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X SyndromeA Pilot Study Exploring the Safety and Synergistic Effect of a Minocycline/Lovastatin Combined Treatment on the Behavior of Individuals With Fragile X Syndrome; Validation of New Biochemical and Neurophysiological Markers (LovaMiX)Fragile X SyndromeDrug: Minocycline, then Minocycline/Lovastatin;Drug: Lovastatin, then Minocycline/LovastatinUniversité de SherbrookeFRAXA Research FoundationCompleted8 Years45 YearsAll22Phase 2Canada
2NCT02998151
(ClinicalTrials.gov)
January 20161/12/2016Neurophysiological and Acute Pharmacological Studies in FXS PatientsNeurophysiological and Acute Pharmacological Studies in FXS PatientsFragile X SyndromeDrug: Acamprosate;Drug: Lovastatin;Drug: Minocycline;Drug: Placebo;Drug: BaclofenChildren's Hospital Medical Center, CincinnatiEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Completed15 Years55 YearsAll29Early Phase 1United States
3NCT02642653
(ClinicalTrials.gov)
January 201621/12/2015Combining Lovastatin and a Parent-Implemented Language Intervention for Fragile X SyndromeCombining Lovastatin and a Parent-Implemented Language Intervention in a Multimodal Treatment for Fragile X SyndromeFragile X Syndrome;Genetic DiseasesDrug: Lovastatin;Other: PlaceboUniversity of California, DavisNULLCompleted10 Years17 YearsAll30Phase 4United States

263. 脳腱黄色腫症


臨床試験数 : 6 薬物数 : 11 - (DrugBank : 2) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 4
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00004346
(ClinicalTrials.gov)
January 199618/10/1999Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous XanthomatosisEffects of Diet and Medication in Patients With Cerebrotendinous Xanthomatosis (CTX)Cerebrotendinous XanthomatosisDrug: chenodeoxycholic acid;Drug: lovastatinNational Center for Research Resources (NCRR)Oregon Health and Science UniversityRecruitingN/AN/ABoth5Phase 2United States

280. 巨大動静脈奇形(頚部顔面又は四肢病変)


臨床試験数 : 27 薬物数 : 30 - (DrugBank : 15) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 153
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04297033
(ClinicalTrials.gov)
January 1, 202121/2/2020Lovastatin for Treatment of Brain Arteriovenous MalformationsLovastatin for Treatment of Brain Arteriovenous Malformations:a Double-blind, Placebo-controlled Randomized TrialCerebral Arteriovenous MalformationDrug: Lovastatin;Drug: PlaceboBeijing Tiantan HospitalNULLNot yet recruiting18 YearsN/AAll1244Phase 2China

310. 先天異常症候群


臨床試験数 : 11 薬物数 : 20 - (DrugBank : 10) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 7
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01110642
(ClinicalTrials.gov)
July 201122/4/2010Novel Treatment for Syndromic IchthyosesOpen-label, Pilot Study to Assess Cholesterol-Lovastatin Solution in the Treatment of Syndromic IchthyosesSyndromic Ichthyoses;CHILD Syndrome;Smith Lemli Opitz Syndrome;Conradi SyndromeDrug: LovastatinNorthwestern UniversityNULLWithdrawn1 YearN/ABoth0Phase 2United States